Savara SVRA
NASDAQ SVRA
$5.37 +0.00 (+0.00%)
As of: Sep 4, 2026 · 3:59 PM EDT

Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026)

Savara (SVRA) posted quarterly Net Income towards Common Stockholders of -$37.3 million for Q1 2026, down 39.96% year-over-year from -$62.1 million in Q1 2025, and down 15.66% quarter-over-quarter from -$32.2 million in Q4 2025.

Analysis

Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Savara (SVRA) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$37.3 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 39.96% year-over-year to -$37.3 million; the TTM figure through Mar 2026 stood at -$129.5 million (down 26.73% YoY), while the FY2025 annual figure was -$118.8 million, down 23.94% from the prior year.
  • Net Income towards Common Stockholders retreated to -$37.3 million in Q1 2026 per SVRA's latest filing, from -$32.2 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$8.3 million in Q1 2022 and bottomed at -$37.3 million in Q1 2026.
  • Historically, Net Income towards Common Stockholders has averaged -$20.3 million across 5 years, with a median of -$20.3 million in 2024.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders advanced 18.76% — and 2024, when it sank 94.38%.
  • Savara's Net Income towards Common Stockholders stood at -$10.3 million in 2022, then tumbled by 56.3% to -$16.1 million in 2023, then slumped by 80.41% to -$29.0 million in 2024, then slipped by 10.99% to -$32.2 million in 2025, then decreased by 15.66% to -$37.3 million in 2026.
  • Business Quant data shows SVRA's Net Income towards Common Stockholders at -$37.3 million in Q1 2026, -$32.2 million in Q4 2025, and -$29.6 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Savara 1.36 Bn 1.36 Bn - -40.23 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -40.23 Mn
Mar 31, 2026 -37.28 Mn
Dec 31, 2025 -32.24 Mn
Sep 30, 2025 -29.56 Mn
Jun 30, 2025 -30.40 Mn
Mar 31, 2025 -26.64 Mn
Dec 31, 2024 -29.04 Mn
Sep 30, 2024 -24.25 Mn
Jun 30, 2024 -22.24 Mn
Mar 31, 2024 -20.35 Mn
Dec 31, 2023 -16.10 Mn
Sep 30, 2023 -16.60 Mn
Jun 30, 2023 -11.44 Mn
Mar 31, 2023 -10.56 Mn
Dec 31, 2022 -10.30 Mn
Sep 30, 2022 -10.39 Mn
Jun 30, 2022 -9.16 Mn
Mar 31, 2022 -8.30 Mn
Dec 31, 2021 -11.31 Mn
Sep 30, 2021 -10.55 Mn